Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HuMAB companies -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (383)	5/3/2002 2:59:09 PM
From: nigel bates	Respond to of 1022

Most of the big pharma collaborations were 2001/2000 deals But that's what I have problems with understanding: three pharma deals in 1998 which don't seem to have born fruit - Schering in February, BMY June, and a major deal with Novartis in November... and nothing in the clinic yet. I am looking at the two mAbs CAT/HGSI have in the clinic from a 1999 collaboration, and wondering if it is just a flash in the pan, or does it mean something. I'm with you on the drugs request, providing we understand that it's ethical. <g> nig

To: keokalani'nui who wrote (383)	5/3/2002 5:10:53 PM
From: nigel bates	Respond to of 1022

MEDX contd. They were claiming this in August 2000 (if not earlier) T-12 Development(SM) offering the capability of moving from target to trial in approximately 12 months... It's still on the website - We believe that a distinct advantage of Medarex's fully human antibodies is their potential for accelerated development. By combining our technology for creating fully human antibodies with our in-house development and clinical supply manufacturing expertise, we have been able to progress from immunization to IND filing in less than 12 months through our T-12 Development Program. If a number of mAbs don't hit the clinic fairly soon, then I'm smelling the delicate aroma of BS. nig